템페스트 테라퓨틱스(TPST)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.01 (-13.25%), 시가총액 $0.03B, 52주 범위 $1.52 ~ $11.83.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, Ca
템페스트 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
템페스트 테라퓨틱스의 현재 주가는 $1.01 (-13.25%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
템페스트 테라퓨틱스의 시가총액은 약 $0.03B입니다.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small mo